Seeking a Complete Response in Hematologic Cancers

Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL). 
BY JASON HARRIS
PUBLISHED: MAY 16, 2017
For patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL) after the Richter transformation, achieving a complete response (CR) after ABVD chemotherapy provided the best chance for survival, according to a study published in the American Journal of Hematology.

“The achievement of CR with ABVD was the strongest significant and independent predictor of survival,” lead author Francesca Romana Mauro, M.D., Ph.D., and co-investigators wrote. “While the median survival of patients who achieved CR was over 17 years, it was only seven months for those who failed to achieve a CR.

The researchers added that a low International Prognostic Score (IPS) and minimum interval of 12 months from the end of prior CLL treatment to a diagnosis of HL, which is a rare variant of RS, were the most important factors determining whether a patient had a complete response.

From July 1994 to December 2015, 33 (0.7 percent) of 4,680 patients with CLL being treated at 10 medical centers in Italy developed biopsy-proven HL. Nearly 80 percent of patients had stage 3/4 disease and half of patients had an IPS of 4 or higher. Median age was 61 at CLL diagnosis and 70 at HL diagnosis. The median interval from CLL to the diagnosis of HL was 90 months (range, 0-258). CLL and HL were diagnosed simultaneously in three cases.

More than 80 percent of patients had been previously treated for CLL prior to the diagnosis of HL and of those, 48 percent were diagnosed within 12 months of their final CLL treatment. Median number of prior treatments was two and 67 percent of patients had received fludarabine.

Twenty-two patients (66.6 percent) were treated with the ABVD regimen. Six patients received Rituxan (rituximab) along with ABVD. The median number of administered courses of ABVD was six (range, two to six) and 12 patients (55 percent) received six courses.

The overall response rate (ORR) was 77.3 percent for patients treated with ABVD, with a CR of 68 percent. Researchers observed a significantly lower CR rate in patients with an IPS 4 or higher compared with those who had IPS less than 3 (27.3 percent vs 81.8 percent). Patients who were diagnosed with HL within 12 months of their last CLL treatment also had a lower CR rate (45 percent vs 55 percent). Prior treatment with fludarabine and the addition of rituximab to ABVD did not have a significant effect on CR rate.

Twenty-two patients (64 percent) in the study died; HL was the cause of death for 15 (71 percent). Four patients died of infection and two died of heart failure. Median survival from HL diagnosis was 37.8 months.

As with CR, treatment with fludarabine and the addition of Rituxan to ABVD did not have a significant effect on survival.

“Patients with advanced disease should be investigated by PET/CT and positive lymph nodes should be biopsied,” Mauro, who works in the Department of Cellular Biotechnologies and Hematology at Sapienza University in Rome, Italy, said in an email to CURE. “This is important to address the correct treatment. Patients who respond to ABVD show a very good prognosis.”

Pallawi Torka, M.D., assistant professor of oncology in the Lymphoma & Myeloma Division at Roswell Park Cancer Institute. She said that treating HL-Richter syndrome (HL-RS) is challenging because patients tend to be elderly, have multiple co-morbidities and poor bone marrow reserve and are at increased risk for cardiac complications. However, she added that “ABVD is a worthwhile frontline regimen” in patients with good performance status (PS) and a low comorbidity score.

“These findings reiterate the importance of a PET scan and rebiopsy for patients with CLL/SLL [small lymphocytic lymphoma] at the time of relapse, especially if the growth kinetics are more rapid than expected, or if response is incongruent between different sites,” Torka said. “The threshold of using newer therapies such as brentuximab vedotin [Adcetris] and checkpoint inhibitors should be low in patients with borderline PS due to the high infection risk with ABVD in this population. Since most cases of HL-RS are EBV [Epstein-Barr Virus] driven, checkpoint inhibitors have the potential to be highly effective in this condition.

“Patients who fail to achieve a CR with ABVD and have a good PS should be transitioned to salvage high-dose therapy and stem cell transplant, if eligible. The decision regarding autologous stem cell transplant versus allogeneic hematopoietic stem cell transplantation (allo-SCT) is usually highly individualized. While allo-SCT is preferable, as it has a potential to cure the underlying CLL, most patients will not be eligible due to advanced age and comorbidities.”
 
 

Talk about this article with other patients, caregivers, and advocates in the Lymphoma Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
3 Times Cancer Was Fun
Cobra, baseball cards and two guys who always let me know I wasn't dead.
CAR T-Cell Therapy Yescarta Approved to Treat Non-Hodgkin Lymphoma
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.
New Hodgkin Lymphoma Therapy in the Pipeline
Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma
Related Videos
Cancer Survivor Celebrates by Dancing with Scripps Doctor
Irene Hutchins, M.D., and her patient Steve Valentine, both accomplished ballroom dancers, made a pact to dance together once he had recovered from late-stage Burkitt lymphoma. They performed their victory dance June 11 during Cancer Survivors Day at Scripps Green Hospital, in La Jolla, California, where Hutchins treated Valentine.
Fred R. Hirsch Discusses His Own Cancer Diagnosis
Fred R. Hirsch, from the University of Colorado and IASLC, discusses some of the unique challenges he faced as a patient.
Susan Thornton on Unmet Needs in Cutaneous Lymphoma
Susan Thornton provides an overview of the unmet needs in cutaneous lymphoma.
x
//For side ad protocol